CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: A case report and literature review

Sheetal M. Kircher, Sandeep Gurbuxani, Sonali M. Smith

Research output: Contribution to journalArticle

Abstract

Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of non-Hodgkin's lymphoma characterized by an aggressive phenotype and poor outcome in the vast majority of cases. Substantial portions of patients have either no prior diagnosis of celiac disease or have a subacute course of celiac disease followed by EATL diagnosis. We report a case of a 72-year-old African American male without history of gastrointestinal intolerance who presented with acute abdominal pain and weight loss leading to the eventual diagnosis of gastric EATL. Despite an initial promising clinical and radiographic response to cyclophosphamide, doxorubicin, vincristine, and prednisone plus alemtuzumab, the disease rapidly progressed with a fatal outcome. This case and review of the literature highlights the features of this uncommon disease and addresses both the diagnostic and therapeutic challenges of this aggressive malignancy. We also discuss our experience with the use of fluoro-2-deoxy-d-glucose positron emission tomography in monitoring treatment response.

Original languageEnglish (US)
Pages (from-to)19-23
Number of pages5
JournalJournal of Gastrointestinal Cancer
Volume38
Issue number1
DOIs
StatePublished - Jan 1 2007

Keywords

  • Alemtuzumab
  • Celiac disease
  • EATL (enteropathy-associated T-cell lymphoma)
  • FDG-PET
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: A case report and literature review'. Together they form a unique fingerprint.

  • Cite this